Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels
Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels
复制标题
DOI：
10.1016/j.ygyno.2011.07.034
复制
发表时间：
2011-11-01
影响因子：
4.7
通讯作者：
Moses, Marsha A.
中科院分区：
文献类型：
--
作者：
Coticchia, Christine M.;Curatolo, Adam S.;Moses, Marsha A.
Objective.确定尿基质金属蛋白酶（MMPs）是否可预测CA 125水平低于正常阈值35 U/mL的患者是否存在卵巢癌，这是一组目前尚无卵巢癌生物标志物的关键患者。为了确定这些非侵入性生物标志物是否也在一般卵巢癌患者群体中提供临床有用的信息。ELISA分析和底物凝胶电泳检测了所有卵巢癌患者（n = 97）、CA 125的患者、CA 125的患者和CA 125的患者尿MMP-2、MMP-9、MMP-9/中性粒细胞明胶酶相关脂质运载蛋白（NGAL）复合物和MMP-9二聚体的水平和活性。
Objective. To determine whether urinary matrix metalloproteinases (MMPs) predict the presence of ovarian cancer in patients with CA125 levels below the normal threshold of 35 U/mL, a critical group of patients for whom no ovarian cancer biomarker is currently available. To determine whether these noninvasive biomarkers provide clinically useful information in the general ovarian cancer patient population as well.Methods. ELISA analyses and substrate gel electrophoresis detected the levels and activity of urinary MMP-2, MMP-9, MMP-9/neutrophil gelatinase-associated lipocalin (NGAL) complex, and MMP-9 dimer in all ovarian cancer patients (n = 97), those with CA125